Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Guilford Gliadel Wafer Initial Surgery Indication To Launch In First Quarter

  • News

Executive Summary

Guilford anticipates an approval for Gliadel Wafer in newly diagnosed malignant glioma during the first quarter

You may also be interested in...



Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit

Guilford's marketing of Gliadel for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight the survival benefit, the company said after receiving the supplemental indication

Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit

Guilford's marketing of Gliadel for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight the survival benefit, the company said after receiving the supplemental indication

Guilford Gliadel Survival Data Could Address FDA “Non-Approvable” Letter

Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's March 19 "non-approvable" letter for a newly diagnosed malignant glioma indication

Table

View full table

Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS041279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By